Similarly to what was observed in the VL51 model, we found that Bcl-2 phosphorylation and expression levels were significantly reduced in CLL cells from idelalisib-resistant/intolerant patients relative to treatment naïve patients (Supplementary Fig. 5a). Here, BCL2 is linked to B-cell chronic lymphocytic leukemia.